MBIO - Mustang Bio Inc Stock Price, Fair Value and News

0.32USD+0.02 (+6.67%)Market Closed

Market Summary

USD0.32+0.02

Market Closed

6.67%

MBIO Stock Price

View Fullscreen

MBIO RSI Chart

MBIO Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

3.39

Price/Free Cashflow

-0.1

MBIO Price/Sales (Trailing)

MBIO Profitability

Return on Equity

811.25%

Return on Assets

-274.81%

Free Cashflow Yield

-1.0K%

MBIO Fundamentals

MBIO Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-90.95%

Rev. Growth (Qtr)

-70.29%

MBIO Earnings

Earnings (TTM)

-40.1M

Earnings Growth (Yr)

68.9%

Earnings Growth (Qtr)

39.75%

Breaking Down MBIO Revenue

Last 7 days

23.1%

Last 30 days

-15.8%

Last 90 days

-75.2%

Trailing 12 Months

-92.4%

How does MBIO drawdown profile look like?

MBIO Financial Health

Current Ratio

0.53

MBIO Investor Care

Shares Dilution (1Y)

39.04%

Diluted EPS (TTM)

-4.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.1M	0	0	0
2023	1.8M	2.1M	1.6M	0
2022	367.0K	310.0K	894.0K	1.4M
2021	579.0K	522.0K	435.0K	0
2020	1.4M	1.1M	885.0K	708.0K
2019	575.0K	815.0K	1.1M	1.3M
2018	560.5K	573.5K	567.5K	569.0K
2017	138.1K	260.3K	382.4K	504.5K
2016	0	0	0	16.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Mustang Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	fortress biotech, inc.	acquired	-	-	419,092	-
Jul 05, 2023	zelefsky michael j	acquired	-	-	7,246	-
Jul 05, 2023	rosenwald lindsay a md	acquired	-	-	7,246	-
Jul 05, 2023	chill adam j.	acquired	-	-	7,246	-
Jul 05, 2023	herskowitz neil	acquired	-	-	7,246	-
Jul 05, 2023	weiss michael s	acquired	-	-	7,246	-
Apr 24, 2023	litchman manuel md	acquired	-	-	5,000	president and ceo
Jan 06, 2023	fortress biotech, inc.	acquired	-	-	2,807,010	-
Sep 13, 2022	rosenwald lindsay a md	bought	2,582	0.5164	5,000	-
Sep 13, 2022	litchman manuel md	bought	2,582	0.5164	5,000	-

Which funds bought or sold MBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Clear Point Advisors Inc.	unchanged	-	-	1.00	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	10,512	10,512	-%
May 15, 2024	Royal Bank of Canada	added	293	1,000	1,000	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	14.00	14.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	24.86	-327	8,268	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-51.81	-369,881	218,400	-%
May 15, 2024	Squarepoint Ops LLC	new	-	15,543	15,543	-%
May 15, 2024	PACIFIC CAPITAL WEALTH ADVISORS, INC	unchanged	-	-2.00	6.00	-%
May 15, 2024	OLIVER LAGORE VANVALIN INVESTMENT GROUP	sold off	-100	-12.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-31.28	-134	151	-%

Are Funds Buying or Selling MBIO?

Are funds buying MBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MBIO

No. of Funds

Unveiling Mustang Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	974,907	SC 13G
Jan 13, 2023	fortress biotech, inc.	20.7%	22,880,620	SC 13D/A
Jul 08, 2022	blackrock inc.	2.2%	2,263,156	SC 13G
Feb 04, 2022	blackrock inc.	6.2%	5,754,566	SC 13G
Apr 12, 2021	blackrock inc.	4.7%	3,984,922	SC 13G/A
Feb 02, 2021	blackrock inc.	5.2%	3,344,681	SC 13G

Recent SEC filings of Mustang Bio Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 13, 2024	424B3	Prospectus Filed
May 02, 2024	8-K	Current Report
May 01, 2024	424B4	Prospectus Filed
Apr 29, 2024	S-1/A	Initial Public Offering
Apr 29, 2024	EFFECT	EFFECT
Apr 29, 2024	EFFECT	EFFECT
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	S-1/A	Initial Public Offering
Apr 29, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to Mustang Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Mustang Bio Inc News

Latest updates

Mustang Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-70.3%	41.00	138	429	453	560	669	77.00	73.00	75.00	85.00	134	141	162	142	263	318	406	387	152	138	138
Operating Expenses	-49.2%	5,231	10,307	13,891	16,321	19,432	18,848	18,241	19,638	17,077	14,440	15,087	20,738	10,427	14,121	11,520	15,923	9,996	10,212	9,754	11,875	7,656
S&GA Expenses	-100.0%	-	2,131	3,055	2,321	2,395	3,389	3,077	3,349	2,364	2,538	3,469	2,405	2,153	2,991	1,956	2,050	1,987	3,189	2,344	1,651	1,340
Interest Expenses	-100.0%	-	4.00	2,932	1,176	1,160	1,034	935	230	3.00	4.00	4.00	-2,313	2,687	619	600	604	578	574	11.00	8.00	-
Net Income	48.4%	-5,191	-10,058	-16,235	-16,693	-19,634	-18,997	-19,099	-19,795	-17,005	-14,359	-14,957	-20,608	-12,952	-14,598	-11,857	-16,209	-10,168	-10,399	-9,613	-11,770	-7,518
Net Income Margin	4.6%	-37.79*	-39.63*	-33.90*	-42.31*	-56.22*	-87.18*	-244.99*	-194.03*	-153.86*	-120.45*	-109.01*	-84.77*	-62.84*	-46.80*	-35.40*	-36.73*	-38.73*	-48.22*	-59.12*	-53.89*	-60.78*
Free Cashflow	55.5%	-5,351	-12,023	-12,426	-17,808	-15,384	-16,892	-17,881	-17,623	-11,749	-13,786	-16,038	-10,172	-10,262	-8,132	-10,678	-10,381	-9,329	-9,434	-6,782	-6,827	-4,948

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.8%	15.00	18.00	21.00	29.00	74.00	92.00	109	122	137	125	135	143	142	110	86.00	97.00	69.00	73.00	84.00	93.00	50.00
Current Assets	-18.6%	9.00	11.00	14.00	23.00	61.00	79.00	94.00	109	124	112	122	131	131	100	76.00	86.00	58.00	63.00	74.00	83.00	42.00
Cash Equivalents	-72.5%	2.00	6.00	10.00	15.00	58.00	76.00	91.00	107	122	111	121	130	129	99.00	75.00	85.00	57.00	62.00	73.00	83.00	36.00
Net PPE	-8.8%	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	10.9%	20.00	18.00	17.00	15.00	44.00	46.00	45.00	40.00	40.00	13.00	12.00	8.00	8.00	11.00	10.00	26.00	23.00	22.00	21.00	21.00	22.00
Current Liabilities	13.4%	17.00	15.00	14.00	13.00	13.00	15.00	14.00	11.00	11.00	11.00	10.00	6.00	7.00	10.00	8.00	15.00	10.00	8.00	6.00	6.00	7.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00	3.00	1.00	-	-	-
Shareholder's Equity	-4118.7%	-4.94	0.00	4.00	14.00	30.00	46.00	64.00	82.00	97.00	112	122	135	133	98.00	76.00	71.00	46.00	52.00	62.00	71.00	28.00
Retained Earnings	-1.4%	-386	-381	-372	-362	-346	-329	-309	-290	-271	-251	-231	-214	-200	-185	-164	-151	-137	-125	-109	-99.08	-88.68
Additional Paid-In Capital	0.2%	381	381	376	376	376	375	374	373	369	360	354	350	334	276	241	223	183	172	172	171	117
Shares Outstanding	30.8%	11.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	6.00	6.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
Float	-	-	-	-	39.00	-	-	-	49.00	-	-	-	-	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	26.6%	-5,321	-7,254	-12,023	-12,392	-17,808	-15,289	-15,913	-17,575	-16,289	-14,703	-11,289	-12,095	-15,580	-9,475	-10,124	-7,568	-10,152	-9,490	-8,830	-8,778	-6,483
Share Based Compensation	-59.6%	76.00	188	100	45.00	235	473	496	650	664	881	884	547	996	619	606	957	805	490	1,120	622	432
Cashflow From Investing	100.0%	-	-30.00	5,950	-34.00	-	-420	-892	-306	-1,334	-1,477	-990	-2,441	-458	-1,464	-1,608	-814	-526	-1,391	-899	4,198	12,001
Cashflow From Financing	-98.8%	49.00	3,956	250	-30,287	-	1.00	800	3,034	30,221	4,919	3,235	15,088	47,605	33,492	1,622	37,929	5,079	-	-111	51,614	13,613

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MBIO Income Statement

2024-03-31

Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 3,804	$ 14,000
General and administrative	1,427	2,321
Total operating expenses	5,231	16,321
Loss from operations	(5,231)	(16,321)
Other income (expense)
Other income	0	351
Interest income	41	453
Interest expense	(1)	(1,176)
Total other income (expense)	40	(372)
Net Loss	$ (5,191)	$ (16,693)
Net loss per common share outstanding, basic	$ (0.46)	$ (2.06)
Net loss per common share outstanding, diluted	$ (0.46)	$ (2.06)
Weighted average number of common shares outstanding, basic	11,253,767	8,093,662
Weighted average number of common shares outstanding, diluted	11,253,767	8,093,662

MBIO Balance Sheet

2024-03-31

Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 1,337	$ 6,234
Other receivables	6,738	3,879
Prepaid expenses and other current assets	1,165	1,233
Total current assets	9,240	11,346
Property, plant and equipment, net	2,962	3,247
Restricted cash	375	750
Other assets	530	833
Operating lease right-of-use asset, net	1,485	1,566
Total Assets	14,592	17,742
Current Liabilities:
Accounts payable and accrued expenses	15,014	14,017
Operating lease liabilities - short-term	570	520
Total current liabilities	17,438	15,371
Deferred income	270	270
Operating lease liabilities - long-term	1,827	1,978
Total Liabilities	19,535	17,619
Commitments and Contingencies (Note 11)
Stockholders' Equity
Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Common stock issuable, zero and 419,089 shares as of March 31, 2024 and December 31, 2023, respectively	0	591
Additional paid-in capital	381,218	380,502
Accumulated deficit	(386,162)	(380,971)
Total Stockholders' Equity	(4,943)	123
Total Liabilities and Stockholders' Equity	14,592	17,742
Related Party [Member]
Current Liabilities:
Payables and accrued expenses - related party	1,854	834
Class A common shares
Stockholders' Equity
Common stock ($0.0001 par value), 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively	0	0
Common shares
Stockholders' Equity
Common stock ($0.0001 par value), 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively	$ 1	$ 1

About Mustang Bio Inc

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

CEO	Dr. Manuel Litchman M.D.
WEBSITE	mustangbio.com
INDUSTRY	Biotechnology
EMPLOYEES	113

Mustang Bio Inc Frequently Asked Questions

What is the ticker symbol for Mustang Bio Inc? What does MBIO stand for in stocks?

MBIO is the stock ticker symbol of Mustang Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mustang Bio Inc (MBIO)?

As of Fri May 17 2024, market cap of Mustang Bio Inc is 3.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBIO stock?

You can check MBIO's fair value in chart for subscribers.

What is the fair value of MBIO stock?

You can check MBIO's fair value in chart for subscribers. The fair value of Mustang Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mustang Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mustang Bio Inc a good stock to buy?

The fair value guage provides a quick view whether MBIO is over valued or under valued. Whether Mustang Bio Inc is cheap or expensive depends on the assumptions which impact Mustang Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBIO.

What is Mustang Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MBIO's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 3.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBIO PE ratio will change depending on the future growth rate expectations of investors.